Diffuse Intrinsic Pontine Glioma DIPG (Diffuse Intrinsic Pontine Glioma) is a highly aggressive brain tumor in children, primarily located in the pons region. It's inoperable due to the tumor’s location, and chemotherapy agents have the inability to cross the blood-brain barrier. Radiation offers only temporary relief, and the 5-year survival rate has remained at 0% for decades. CAR-T cell therapy, successful in blood cancers, faces challenges in treating solid tumors due to the absence of unique "tumor-only" antigens that are not shared with normal cells.
Logic Gated CAR-T A University of Colorado research group led by Drs. Venkataraman and Kohler have developed and assessed the functionality of innovative ‘logic-gated’ AND CAR T-cells. They are designed to target two distinct antigens highly co-prevalent on DIPG cells and not co-expressed in normal cells. There are two specific logic-gated CAR-T versions: one targeting CD99 and CD56 (also effective in AML) and another targeting CD99 and B7H3 (also effective in Ewing sarcoma and Ependymoma). These novel CAR T-cells mark the pioneering approach to targeting DIPG-specific antigens and represent the first application of logic-gated CAR-T cell therapy for DIPG.
Download Summary Document Here:
https://cuamc.technologypublisher.com/files/sites/cu6133h_-_novel_cd99_and_b7h3_logic_gated_car_t_ncs_20231.pdf